Convert Webinar time to your Time zone
The field of Orthobiologics has gained traction in treating bone, cartilage, tendons/ligaments, and muscle ailments. However, the effectiveness of these treatments remains inconclusive due to varying professional opinions on patient indications, administration protocols, and available options/devices.. To address these issues, ESSKA has launched the ORthoBIologics InitiaTive (ORBIT) to establish a standardized approach to orthobiologic treatments. Focused on injectable options, ESSKA-ORBIT consensuses aim to address the use of blood-derived products and cell-based therapies in knee OA. After the delivery of the blood derived products consensus in 2022, this consensus, focused on cell-based therapy, has been completed as part 2 of this initiative.
The "Use of Injectable Orthobiologics for Knee OsteoArthritis. Part 2: Cell-based Therapy (CBT). A formal ESSKA-ORBIT Consensus" summary and complete report are available below.
Moderators: Dr Laura de Girolamo (Italy) & Dr Lior Laver (Israel)
